Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322931 | 1.00 | TRPM8 (0.38) | TRPM8TRPV1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL3323275 | 0.89 | TRPV1 (0.37) | TRPM8TRPV1HCRTR1HCRTR2 | |
| SCHEMBL3323280 | 0.89 | TRPV1 (0.37) | TRPM8TRPV1HCRTR1HCRTR2 | |
| SCHEMBL3323451 | 0.85 | TRPV1 (0.32) | TRPV1P2RX7SCN9AHTR2AHTR2C | |
| SCHEMBL3323444 | 0.85 | TRPV1 (0.32) | TRPV1P2RX7SCN9AHTR2AHTR2C | |
| SCHEMBL3322941 | 0.82 | TRPM8 (0.39) | TRPM8TRPV1HTR2AHTR2CHTR2B | |
| SCHEMBL3322936 | 0.82 | TRPM8 (0.39) | TRPM8TRPV1HTR2AHTR2CHTR2B | |
| SCHEMBL3322165 | 0.78 | TRPV1 (0.44) | TRPM8TRPV1 | |
| SCHEMBL3324035 | 0.78 | TRPV1 (0.44) | TRPM8TRPV1 | |
| SCHEMBL3324617 | 0.77 | TRPV1 (0.43) | TRPM8TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPM8 8/4885TRPV1 1/4885P2RX7 53/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPM8 8/4885TRPV1 1/4885P2RX7 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.